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Abstract
Gender disparities in tuberculosis (TB) cases are reported worldwide, and socio-cultural factors have been proposed as possible causes.
To date, gender differences in treatment outcomes of TB patients remain controversial. In this prospective observational study, newly
diagnosed, culture-proven TB patients from six hospitals in Taiwan were enrolled for analysis. Gender differences in demographic char-
acteristics and treatment outcomes, including sputum conversion and on-treatment mortality, were analysed accordingly. From January
2007 through to December 2009, a total of 1059 patients were enrolled, including 819 (77.3%) males and 240 (22.7%) females. The
ratio of male gender was around 5060% in TB patients below 35 years and >80% for those older than 65 years. When compared with
the female patients, the male patients were older, more likely to have the habit of smoking, chronic obstructive pulmonary disorder,
malignancy and liver cirrhosis, and more likely to present with haemoptysis, body weight loss and pleural effusion. Regarding treatment
outcomes, male gender is associated with a lower 2-month sputum culture conversion rate (78.8% vs. 89.3%, p 0.002) and higher on-
treatment mortality (21.1% vs. 12.1%, p 0.002). Kaplan–Meier survival analysis demonstrated signiﬁcantly higher mortality in the men
(p 0.005). In multivariate analysis, male gender was an independent risk factor for 2-month sputum culture un-conversion (OR, 1.96;
95% CI, 1.12–3.41). Our ﬁndings suggest that male gender is associated with older age, more co-morbidities and worse treatment out-
comes. Gender-speciﬁc strategies, including active case ﬁnding in elderly women and smoking cessation in male patients, are warranted
to optimize TB management.
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Introduction
Tuberculosis (TB) is an airborne-transmitted infectious dis-
ease with high morbidity and mortality around the world. It
is estimated that one-third of the world’s total population,
nearly two billion people, are infected with TB bacilli and
that this caused 1.2–1.5 million deaths in 2010 [1]. Despite a
high degree of medical accessibility, abundant medical
resources and the implementation of Direct Observation
Therapy/Short course (DOTS) programmes since 2006, Tai-
wan remains a TB endemic area. From 2008 to 2010, the
incidence rates of TB in Taiwan were 62.0, 57.8 and 57.2
per 100 000 population, respectively [2]. Our recent studies
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reported that the 2-month sputum culture conversion rate
was 73.6%, and the 1-year cumulative mortality rate 22.5% in
pulmonary tuberculosis patients in Taiwan [3,4].
Gender disparities in TB epidemics are striking and have
been well described in previous studies [5–10]. The World
Health Organization reported that nearly twice as many men
as women have been diagnosed with TB globally [1]. The
imbalance in incidence is usually explained by social-cultural-
economical factors. The ﬁnancial dependence and cultural
inequality of women result in a lack of autonomy in some
areas, which may reduce medical accessibility and treatment
adherence [6,8,9]. Gender-speciﬁc social roles may also
require men to have more social contact, thereby increasing
the risk of TB exposure [5,10]. Of note, most of these
hypotheses were based on observations from areas with lim-
ited medical resources and also with signiﬁcant socio-cultural
differences between genders. Meanwhile, the possible impact
of sexual hormones and the differences between men and
women in immunological reactions have also been proposed
as factors causing men to be more susceptible to Mycobacte-
rium tuberculosis infection [11,12].
The impact of gender in treatment outcomes has less fre-
quently been analysed and has revealed inconsistent results.
If the socio-cultural characteristics play a role in gender dif-
ferences in TB epidemics, they may affect the treatment out-
comes between genders. Clarifying the gender disparities in
treatment outcomes also provides important information for
public health strategies against TB disease. The main purpose
of the present study was to identify the gender differences
of treatment outcomes in TB patients. The clinical and radio-
graphic presentations of TB in male and female patients were
also compared.
Methods
Patients and setting
This prospective observational study was conducted at six
hospitals in Taiwan, including ﬁve tertiary medical centres
and one regional hospital that specialized in pulmonary
diseases. The involved hospitals were located across all of
Taiwan. Newly diagnosed, culture-proven tuberculosis
patients from January 2007 to December 2009 were eligible
for this study. All patients eligible for recruitment were in-
and outpatients and the recruitment was sequential. Patients
who were younger than 18 years of age, with treatment
default and transferred out were excluded. The demographic
proﬁles (age, gender and co-morbidities) and clinical charac-
teristics (presenting symptoms/signs, smoking habits and his-
tory of previous anti-TB treatment) were obtained from the
patients and/or their caregivers by enrollment interviews.
The ﬁndings from radiography of the chest were reviewed
by the physicians that were in charge of each hospital and
determined at the time of TB diagnosis. The institutional
review boards of all six hospitals approved the study and
informed consent was obtained from each patient before
enrollment.
Treatment of TB
All of the patients were treated with a standard anti-TB treat-
ment that included isoniazid, rifampicin, ethambutol and pyr-
azinamide in the intensive phase for at least 2 months,
followed by a regimen that included isoniazid, rifampicin and
ethambutol in the continuous phase. The regimen was modi-
ﬁed when the drug susceptibility results were available or
when clinically signiﬁcant adverse effects occurred. We used
the adherence to DOTS strategy as a surrogate for treatment
compliance. Newly diagnosed TB patients who started the
DOTS immediately after TB diagnosis and continued without
interruption throughout the treatment course of the initial
2 months were deﬁned as adherence to DOTS strategy.
Treatment outcomes evaluation
In patients with pulmonary involvement, at least two sets of
sputum were collected for AFB smears and Mycobacterium
tuberculosis (MTB) cultures at the end of the second month
after initiation of anti-TB treatment. All of the patients were
prospectively followed until death or completion of anti-TB
treatment. Patients who died for any reason before the com-
pletion of anti-TB treatment were included in the analysis.
The treatment outcomes evaluated in this study included
sputum smear conversion at 2 months, sputum culture con-
version at 2 months, mortality at 2 and 6 months and overall
on-treatment mortality.
Mycobacteriology and genotyping
Sputum smears were examined through Ziehl–Neelsen stain-
ing and MTB cultures were performed in liquid medium
(BACTEC MGIT960) and/or Lowenstein-Jensen solid med-
ium. All clinical isolates were genotyped using a commercial
spoligotyping kit (Isogen Bioscience B.V., Maarssen, the
Netherlands) after genomic DNA extraction [13]. The ‘Beij-
ing strain’ was deﬁned as a deletion from spacer 1 to spacer
34 in the direct repeat region and the presence of (at least
3) spacers in 35–43.
Statistical analysis
Comparisons of demographic and clinical characteristics
were carried out using the chi-squared test or Fisher’s exact
test for categorical variables, and the two-tailed independent
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t-test for continuous variables. The 2- and 6-month sputum
conversion status between male and female TB patients was
compared by the chi-squared test or Fisher’s exact test. The
on-treatment mortality was analysed by Cox proportional-
hazards models. A p value of <0.1 in the unadjusted model
was required for a variable to be entered into the adjusted
model. The odds ratios and hazard ratios with their 95%
conﬁdence intervals were reported accordingly. In survival
time analysis, Kaplan–Meier plots were constructed and log-
rank tests were performed. Signiﬁcance was deﬁned as
p <0.05 (two-tailed). Statistical analysis was performed using
a statistical software package (SPSS version 14.0; SPSS Inc.,
Chicago, IL, USA).
Results
From January 2007 to December 2009, 1090 newly diag-
nosed, culture-proven tuberculosis patients were included
from six hospitals. Twenty-three patients were excluded as
they were <18 years old, three patients were excluded due
to treatment default, and ﬁve patients were excluded due to
being transferred out. Finally, a total of 1059 patients were
enrolled for analysis. Of these patients, 819 (77.3%) were
male and 240 (22.7%) were female. The proportions of male
gender among various age groups are shown in Fig. 1. The
ratio of male gender was around 5060% for those below
35 years, but escalated gradually as the age of the patients
increased. The ratio of male gender was >80% in TB patients
older than 65 years.
The demographic characteristics and clinical presentations
of the male and female TB patients are shown in Table 1. As
compared with the female patients, male TB patients were
more likely to be older (66.8 ± 17.8 years vs. 57.4 ± 21.8
years, p <0.001), have the habit of smoking (35.3% vs. 8.3%,
p <0.001), have chronic obstructive pulmonary disease (8.8%
vs. 1.7%, p <0.001) and have some malignancy (14.9% vs.
7.9%, p 0.005). In Taiwan, most liver cirrhosis is related to
viral hepatitis that is induced by the hepatitis B and hepatitis
C viruses [14], and we found that men were more likely to
have liver cirrhosis (3.9% vs. 1.3%, p 0.043). The drug sus-
ceptibility proﬁles for ﬁrst line anti-TB drugs and genotypes
of MTB isolates were similar between the male and female
patients. In clinical presentations, the male TB patients were
more likely to present with haemoptysis (17.7% vs. 10%,
p 0.004), body weight loss (22.5% vs. 16.3%, p 0.038) and
pleural effusion in chest radiograms (22.2% vs. 10.8%,
p <0.001) when compared with the female patients. The
Beijing genotype was the dominant strain in our patients
(479/1059, 45.2%) and the proportions of the Beijing geno-
type were comparable between male and female patients
(46.4% vs. 41.3%, p 0.16).
Comparisons of treatment outcomes between the male
and female TB patients are shown in Table 2. Male TB
patients were associated with a lower 2-month smear con-
version rate (73.6% vs. 84.2%, p 0.004) and a lower 2-month
culture conversion rate (78.8% vs. 89.3%, p 0.002). Regarding
mortality, male TB patients were associated with higher
6-month mortality (17.2% vs. 10.8%, p 0.017) and higher
overall on-treatment mortality (21.1% vs. 12.1%, p 0.002).
Kaplan–Meier survival curves according to gender demon-
strated higher mortality (p 0.005) in male TB patients
(Fig. 2). Multivariate analyses of the clinical predictors for
treatment outcomes are shown in Table 3. Male gender,
positive pretreatment smear, presence of dyspnoea, presence
of cavity and pleural effusion in radiograms and resistance to
rifampicin were independent predictors for sputum culture
un-conversion at 2 months. Regarding mortality, older age,
co-morbidities of malignancy, renal insufﬁciency, absence of
cough for >3 weeks, presence of fever, anorexia, presence
of consolidative lesions and pleural effusion in radiograms
were independent risk factors associated with higher overall
on-treatment mortality.
Discussion
In this prospective observational study, we demonstrated the
changing pattern of the male/female ratio among various age
groups in Taiwan, a TB endemic area with abundant medical
resources and relatively low socioeconomic disparities
between men and women. The male patients were older,
smoked more frequently, had more co-morbidities and were
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FIG. 1. Male ratios among tuberculosis patients, stratiﬁed by age-
group.
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more symptomatic on initial presentation. Most importantly,
we found that the male TB patients had a lower 2-month
sputum culture conversion rate and higher on-treatment
mortality compared with females. Our ﬁndings disclose the
differences between male and female TB patients with
regards to clinical characteristics and their possible impact
on treatment outcomes. Gender-speciﬁc strategies are
required for better TB control in TB endemic areas.
Older age and co-morbidities associated with senility,
including diabetes, renal insufﬁciency and malignancy, are all
well-documented risk factors for tuberculosis [15–17]. In the
present study, we found that male TB patients were signiﬁ-
TABLE 1. Demographic character-
istics and clinical presentations of
male and female pulmonary tuber-
culosis patientsa
All patients
(n = 1059)
Gender
p value
Male
(n = 819)
Female
(n = 240)
Mean age (SD) 64.7 (19.2) 66.8 (17.8) 57.4 (21.8) <0.001
Previous TB history 98 (9.3%) 80 (9.8%) 18 (7.5%) 0.29
Smoking habit 309 (29.2%) 289 (35.3%) 20 (8.3%) <0.001
Initial sputum smear positive 494 (46.6%) 389 (47.5%) 105 (43.8%) 0.31
With extrapulmonary involvement 94 (8.9%) 70 (8.5%) 24 (10.0%) 0.49
Co-morbid diseases
Diabetes 234 (22.1%) 191 (23.3%) 43 (17.9%) 0.08
COPD 76 (7.2%) 72 (8.8%) 4 (1.7%) <0.001
Malignancy 141 (13.3%) 122 (14.9%) 19 (7.9%) 0.005
Renal insufﬁciency 54 (5.1%) 44 (5.4%) 10 (4.2%) 0.46
Liver cirrhosis 35 (3.3%) 32 (3.9%) 3 (1.3%) 0.043
HIV positive 14 (1.3%) 13 (1.6%) 1 (0.4%) 0.21
Post-gastrectomy 33 (3.1%) 29 (3.6%) 4 (1.7%) 0.14
Drug susceptibility test
Isoniazid resistance 126 (11.9%) 104 (12.7%) 22 (9.2%) 0.14
Rifampicin resistance 68 (6.4%) 55 (6.7%) 13 (5.4%) 0.47
Ethambutol resistance 74 (7.0%) 60 (7.3%) 14 (5.8%) 0.43
Streptomycin resistance 114 (10.8%) 87 (10.6%) 27 (11.3%) 0.78
MDR 62 (5.9%) 49 (6.0%) 13 (5.4%) 0.74
Radiographic presentations
Cavity formation 187 (17.7%) 146 (17.8%) 41 (17.1%) 0.79
Lobar/segmental consolidation 829 (78.3%) 641 (78.3%) 188 (78.3%) 0.98
Bilateral involvement 423 (39.9%) 339 (41.4%) 84 (35.0%) 0.08
Pleural effusion 208 (19.6%) 182 (22.2%) 26 (10.8%) <0.001
Presenting symptoms
Chronic cough 602 (56.8%) 467 (57.0%) 135 (56.3%) 0.83
Haemoptysis 169 (16.0%) 145 (17.7%) 24 (10.0%) 0.004
Dyspnoea 254 (24.0) 199 (24.3%) 55 (22.9%) 0.66
Body weight loss 223 (21.1%) 184 (22.5%) 39 (16.3%) 0.038
Fever 322 (30.4%) 250 (30.5%) 72 (30.0%) 0.88
Malaise 151 (14.3%) 119 (14.5%) 32 (13.3%) 0.64
Anorexia 202 (19.1%) 157 (19.2%) 45 (18.8%) 0.88
Beijing strain infection 479 (45.2%) 380 (46.4%) 99 (41.3%) 0.16
DOTS implementation 520 (49.1%) 396 (48.4%) 124 (51.7%) 0.37
COPD, chronic obstructive pulmonary disorder; HIV, human immunodeﬁciency virus; MDR, multi-drug resistance;
DOTS, directly observed therapy, short course.
aData are presented as mean ± SD or n (%), unless otherwise stated.
TABLE 2. Treatment outcomes between male and female
tuberculosis patientsa
Gender
p valueMale Female
Sputum conversion at 2 months (n = 771)
Smear conversion 437 (73.6%) 149 (84.2%) 0.004
Culture conversion 468 (78.8%) 158 (89.3%) 0.002
Mortality (n = 1059)
At 2 months 90 (11.0%) 18 (7.5%) 0.12
At 6 months 141 (17.2%) 26 (10.8%) 0.017
Overall on-treatment mortality 173 (21.1%) 29 (12.1%) 0.002
Two-month sputum conversion results were available in 771 patients.
aData are presented as mean ± SD or n (%), unless otherwise stated.
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FIG. 2. Kaplan–Meier survival curves of tuberculosis patients strati-
ﬁed by gender. Signiﬁcance was tested using the log-rank test.
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cantly older and had more co-morbidities than female
patients. We further analysed the male/female ratio of TB
patients among various age groups and noted that the pro-
portion of males escalated as age increased. Our ﬁndings
clearly demonstrate that the gender differences in TB epi-
demics in Taiwan mostly occurred in elderly patients. In Tai-
wan, the socio-cultural disparities between genders are not
remarkable and medical accessibility is high, as 99% of the
population is provided with universal medical coverage by
the National Health Insurance Programme. The nearly equal
ratio between genders under the age of 45 indicates the
even status between middle-aged men and women. How-
ever, the dominance of male gender in elderly TB patients is
an important issue worthy of study. Higher probabilities of
co-morbidities in men may contribute to this male predomi-
nance. Neglected socioeconomic barriers may also exist and
hinder healthcare-seeking behaviour in elderly females.
Under-diagnosis of TB in elderly women is a pivotal issue in
TB management and should be carefully evaluated in Taiwan
and other developed countries.
The demographic characteristics and clinical presentations
of male and female TB patients were also evaluated in this
study. Male TB patients were more likely to have the habit
of smoking, which has been well documented as a strong risk
factor for TB occurrence in several cohort studies [18,19].
The higher smoking rate in men may be an important factor
contributing to the higher proportion of men in TB epidemi-
ology. Regarding clinical presentations, women were found
to be less symptomatic as compared with male patients. A
national tuberculosis survey in Bangladesh described a lower
awareness of symptoms among female TB patients [20].
Thorson et al. [21] also reported less advanced radiographic
ﬁndings in women with TB. The absence of respiratory and
constitutional symptoms may lead to a delay in seeking medi-
cal assistance. Less advanced radiographic ﬁndings also make
it less likely that physicians will suspect pulmonary TB.
Although details about delays in diagnosis were not collected
in the present study, all of these factors may contribute to a
delayed diagnosis of TB in women.
The impact of gender in treatment outcomes of TB
patients has been evaluated in previous studies but has
revealed inconsistent results. Higher mortality, greater treat-
ment failure and more default from treatment have been
reported in Mexico, India and Italy [22–24]. In contrast, simi-
lar treatment outcomes between genders have also been
reported in Brazil and Egypt [25,26]. However, gender differ-
ences in sputum conversion have rarely been mentioned
before. Interestingly, we reported a signiﬁcantly lower spu-
tum conversion rate and higher on-treatment mortality in
male TB patients. In multivariate analysis, male gender was
an independent factor associated with failure of 2-month
sputum culture conversion.
In our analysis, we found that the presence of cough for
>3 weeks was associated with lower mortality. In clinical
TABLE 3. Univariate and multivariate analysis of independent factors associated with 2-month culture conversion and on-
treatment mortality in tuberculosis patientsa
Two-month culture conversiona Overall on-treatment mortalityb
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
OR (95% CI) p value OR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Male gender 2.24 (1.34–3.75) 0.002 1.96 (1.12–3.41) 0.018 1.83 (1.23–2.71) 0.003 – –
Age 1.00 (0.99–1.01) 0.93 – – 1.06 (1.04–1.07) <0.001 1.05 (1.03–1.06) <0.001
Smoking habit 1.43 (0.99–2.08) 0.06 – – 0.78 (0.57–1.08) 0.13 – –
Previous anti-TB treatment 2.49 (1.45–4.28) 0.001 – – 0.93 (0.57–1.50) 0.76 – –
Pretreatment smear positive 2.83 (1.91–4.19) <0.001 2.75 (1.78–4.24) <0.001 0.92 (0.69–1.21) 0.53 – –
Diabetes 1.16 (0.76–1.77) 0.50 – – 1.14 (0.82–1.57) 0.44 – –
COPD 1.76 (0.97–3.17) 0.06 – – 1.45 (0.92–2.31) 0.11 – –
Malignancy 1.21 (0.71–2.06) 0.48 – – 3.41 (2.53–4.60) <0.001 2.48 (1.81–3.40) <0.001
Renal insufﬁciency 1.00 (0.40–2.47) 0.99 – – 3.00 (1.94–4.63) <0.001 2.26 (1.43–3.56) <0.001
Gastrectomy 1.02 (0.34–3.07) 0.98 – – 2.69 (1.56–4.62) <0.001 – –
Cough >3 weeks 1.40 (0.96–2.06) 0.09 – – 0.49 (0.37–0.65) <0.001 0.57 (0.42–0.76) <0.001
Haemoptysis 1.12 (0.69–1.82) 0.64 – – 1.15 (0.80–1.66) 0.44 – –
Dyspnoea 2.03 (1.38–3.00) <0.001 1.68 (1.10–2.56) 0.017 1.35 (0.99–1.82) 0.05 – –
Body weight loss 1.28 (0.85–1.93) 0.25 – – 0.76 (0.53–1.09) 0.13 – –
Fever 1.36 (0.93–2.00) 0.11 – – 1.80 (1.37–2.39) <0.001 1.42 (1.06–1.90) 0.020
Anorexia 1.26 (0.81–1.96) 0.31 – – 1.58 (1.15–2.16) 0.005 1.43 (1.03–1.98) 0.031
Cavitary lesion 2.76 (1.85–4.11) <0.001 1.93 (1.24–3.00) 0.004 0.55 (0.35–0.85) 0.007 – –
Lobar/segmental consolidation 1.00 (0.64–1.55) 0.98 – – 1.73 (1.16–2.56) 0.007 1.70 (1.14–2.53) 0.009
Pleural effusion 1.94 (1.25–3.01) 0.003 1.76 (1.09–2.86) 0.021 2.50 (1.87–3.33) <0.001 1.64 (1.20–2.25) 0.002
Resistance to isoniazid 1.60 (0.92–2.79) 0.10 – – 0.98 (0.64–1.51) 0.94 – –
Resistance to rifampicin 3.83 (1.96–7.46) <0.001 3.23 (1.55–6.76) 0.002 0.88 (0.49–1.58) 0.67 – –
DOTS implementation 0.59 (0.410.85) 0.004 0.57 (0.38–0.86) 0.007 0.90 (0.66–1.23) 0.90 – –
OR, odds ratio; CI, conﬁdence interval; HR, hazard ratio; COPD, chronic obstructive pulmonary disorder; DOTS, directly observed therapy, short course.
aOdds ratios and 95% conﬁdence intervals were derived from the logistic regression analysis.
bHazard ratios and 95% conﬁdence intervals were derived from the Cox proportional hazards model.
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practice, the presence of respiratory symptoms, especially
chronic cough, is an important indicator that reminds
clinicians of the possibility of pulmonary tuberculosis in TB
endemic areas. By comparison, pulmonary tuberculosis
patients without remarkable respiratory symptoms are prob-
ably more likely to have a delayed diagnosis. The delayed
diagnosis leads to delayed treatment and worse treatment
outcomes. The association between mortality and the
absence of cough has also been reported in a previous study
[27].
In addition to the aforementioned differences in demo-
graphic characteristics, different hormonal effects between
genders should also be considered as a possible contributor
to inferior outcomes in men. Differences in sexual hormones
may lead to inequalities between genders in tuberculosis.
Several in-vitro studies evaluated the impact of sex hor-
mones on immune response [28–30]. Generally speaking,
oestrogen can enhance the secretion of IFN-c and potentiate
macrophage activation; however, testosterone may inhibit
the immune response. In addition, mice studies have demon-
strated that ovariectomized mice are vulnerable to Mycobac-
terium avium infection, and that oestradiol supplements may
reverse the greater susceptibility [31]. Currently, human
studies evaluating the role of sex hormones in TB infection
are lacking. However, as there are studies indicating that the
immune-modulating effect of sex hormones may potentially
contribute to the gender disparity in TB epidemiology, fur-
ther studies are warranted to elucidate this issue.
Our ﬁndings suggest that even in a developed country
with abundant medical accessibility such as Taiwan, the gen-
der disparities in tuberculosis remain remarkable. The differ-
ences, including demographic characteristics, clinical
presentations and treatment outcomes, highlight the impor-
tance of gender-speciﬁc strategies in TB management. The
lower female ratio in the elderly population and fewer symp-
toms in women raise the concern about delayed diagnosis.
The accessibility of medical treatment to elderly women
should be re-evaluated, and clinicians should be aware of the
lower amount of symptomatic presentations noted among
female TB patients. For men, a campaign of smoking cessa-
tion should be a pivotal issue to help lower TB occurrence.
In addition, early identiﬁcation and optimal control of the
underlying co-morbidities would be helpful in improving the
treatment outcomes of TB patients.
There are several limitations to this study. The duration
of presenting symptoms at TB diagnosis was not recorded in
our patients, and this made it difﬁcult to identify differences
in delays between genders. Five of the six study hospitals
were referral medical centres, and TB patients with a higher
severity or more co-morbidities may have been included,
thus causing bias in the evaluation of treatment outcomes.
We did not divide deaths as being TB related or non-TB
related due to the difﬁculties in evaluating the impact of TB
on mortality. All-cause mortality is more objective and appli-
cable in clinical practice. Finally, the study was performed in
a developed country with a low HIV prevalence, and HIV
testing was not routinely carried out in each patient. This
limited the ability of our ﬁndings to be applied to low to
middle-income countries or HIV endemic areas.
In conclusion, we found that more than three-fourths of
TB patients were male in Taiwan, and that the male/female
ratio was higher in the elderly population. Men with TB were
older, more likely to be smokers and had more co-morbidi-
ties, but women were less symptomatic. Regarding treatment
outcomes, female gender was an independent predictor of 2-
month sputum culture conversion. The gender disparities in
epidemiology and treatment outcomes indicate the impor-
tance of gender-speciﬁc strategies in TB management. Fur-
ther studies focusing on immunological characteristics are
also warranted to elucidate gender differences other than
socio-cultural and clinical factors.
Acknowledgements
This study was funded by the Institute for Biotechnology and
Medicine Industry, Taiwan, and the Taipei Veterans General
Hospital (V97C1-064, V98C1-039, V98A-086, V99C1-181,
V99A-023 and V100A-002).
Transparency Declaration
All authors declare no conﬂict of interest of any nature.
References
1. World Health Organization global tuberculosis control 2011. Avail-
able at: http://www.who.int/tb/publications/global_report/2011/gtbr11_
full.pdf (last accessed 16 June 2012).
2. Centers for disease control, Taiwan: Taiwan tuberculosis control
report 2011 Available at: http://www2.cdc.gov.tw/public/data/
219124871.pdf (last accessed 16 June 2012).
3. Su WJ, Feng JY, Chiu YC, Huang SF, Lee YC. Role of 2-month spu-
tum smears in predicting culture conversion in pulmonary tuberculo-
sis. Eur Respir J 2011; 37: 376–383.
4. Feng JY, Su WJ, Chiu YC et al. Initial presentations predict mortality
in pulmonary tuberculosis patients–a prospective observational study.
PLoS One 2011; 6: e23715.
5. Liefooghe R, Michiels N, Habib S, Moran MB, De Muynck A. Perception
and social consequences of tuberculosis: a focus group study of tuber-
culosis patients in Sialkot, Pakistan. Soc Sci Med 1995; 41: 1685–1692.
E336 Clinical Microbiology and Infection, Volume 18 Number 9, September 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E331–E337
6. Yamasaki-Nakagawa M, Ozasa K, Yamada N et al. Gender difference
in delays to diagnosis and health care seeking behaviour in a rural
area of Nepal. Int J Tuberc Lung Dis 2001; 5: 24–31.
7. Weiss MAC, Somma D, Abouihia A. Gender and tuberculosis: cross-site
analysis and implications of a multi-country study in Bangladesh, India,
Malawi and Columbia. TDR/SDR/SEB/RP/061 Geneva, Switzerland:
WHO 2006.
8. Diwan VK, Thorson A. Sex, gender, and tuberculosis. Lancet 1999;
353: 1000–1001.
9. Karim F, Ahmed F, Begum I, Johansson E, Diwan VK. Female-male
differences at various clinical steps of tuberculosis management in
rural Bangladesh. Int J Tuberc Lung Dis 2008; 12: 1336–1339.
10. Vlassoff C, Garcia Moreno C. Placing gender at the centre of health
programming: challenges and limitations. Soc Sci Med 2002; 54: 1713–
1723.
11. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS
Med 2009; 6: e1000199.
12. Shaaban MA, Abdul Ati M, Bahr GM, Standford JL, Lockwood DN,
McManus IC. Revaccination with BCG: its effects on skin tests in
Kuwaiti senior school children. Eur Respir J 1990; 3: 187–191.
13. Su WJ, Huang CY, Perng RP. Utility of PCR assays for rapid diagnosis
of bcg infection in children. Int J Tuberc Lung Dis 2001; 5: 380–384.
14. Kuo YH, Lu SN, Chen CL et al. Hepatocellular carcinoma surveillance
and appropriate treatment options improve survival for patients with
liver cirrhosis. Eur J Cancer 2010; 46: 744–751.
15. Gustafson P, Gomes VF, Vieira CS et al. Tuberculosis in Bissau: inci-
dence and risk factors in an urban community in sub-saharan africa.
Int J Epidemiol 2004; 33: 163–172.
16. Faurholt-Jepsen D, Range N, Praygod G et al. Diabetes is a risk factor
for pulmonary tuberculosis: a case-control study from Mwanza, Tan-
zania. PLoS One 2011; 6: e24215.
17. Kim HR, Hwang SS, Ro YK et al. Solid-organ malignancy as a risk fac-
tor for tuberculosis. Respirology 2008; 13: 413–419.
18. Jee SH, Golub JE, Jo J, Park IS, Ohrr H, Samet JM. Smoking and risk
of tuberculosis incidence, mortality, and recurrence in south korean
men and women. Am J Epidemiol 2009; 170: 1478–1485.
19. Lin HH, Ezzati M, Chang HY, Murray M. Association between
tobacco smoking and active tuberculosis in Taiwan: prospective
cohort study. Am J Respir Crit Care Med 2009; 180: 475–480.
20. Hamid Salim MA, Declercq E, Van Deun A, Saki KA. Gender differ-
ences in tuberculosis: a prevalence survey done in bangladesh. Int J
Tuberc Lung Dis 2004; 8: 952–957.
21. Thorson A, Long NH, Larsson LO. Chest x-ray ﬁndings in relation to
gender and symptoms: a study of patients with smear positive tuber-
culosis in Vietnam. Scand J Infect Dis 2007; 39: 33–37.
22. Jimenez-Corona ME, Garcia-Garcia L, DeRiemer K et al. Gender dif-
ferentials of pulmonary tuberculosis transmission and reactivation in
an endemic area. Thorax 2006; 61: 348–353.
23. Balasubramanian R, Garg R, Santha T et al. Gender disparities in
tuberculosis: report from a rural DOTS programme in south India.
Int J Tuberc Lung Dis 2004; 8: 323–332.
24. Faustini A, Hall AJ, Mantovani J, Sangalli M, Perucci CA. Treatment
outcomes and relapses of pulmonary tuberculosis in lazio, Italy,
1999–2001: a six-year follow-up study. Int J Infect Dis 2008; 12: 611–
621.
25. Belo MT, Luiz RR, Hanson C et al. Tuberculosis and gender in a pri-
ority city in the state of Rio de Janeiro, Brazil. J Bras Pneumol 2010;
36: 621–625.
26. Kamel MI, Rashed S, Foda N, Mohie A, Loutfy M. Gender differences
in health care utilization and outcome of respiratory tuberculosis in
Alexandria. East Mediterr Health J 2003; 9: 741–756.
27. Low S, Ang LW, Cutter J et al. Mortality among tuberculosis
patients on treatment in Singapore. Int J Tuberc Lung Dis 2009; 13:
328–334.
28. Roden AC, Moser MT, Tri SD et al. Augmentation of T cell levels
and responses induced by androgen deprivation. J Immunol 2004; 173:
6098–6108.
29. Calippe B, Douin-Echinard V, Laffargue M et al. Chronic estradiol
administration in vivo promotes the proinﬂammatory response of
macrophages to TLR4 activation: involvement of the phosphatidylino-
sitol 3-kinase pathway. J Immunol 2008; 180: 7980–7988.
30. Janele D, Lang T, Capellino S, Cutolo M, Da Silva JA, Straub RH.
Effects of testosterone, 17beta-estradiol, and downstream estrogens
on cytokine secretion from human leukocytes in the presence and
absence of cortisol. Ann N Y Acad Sci 2006; 1069: 168–182.
31. Tsuyuguchi K, Suzuki K, Matsumoto H, Tanaka E, Amitani R, Kuze F.
Effect of oestrogen on Mycobacterium avium complex pulmonary
infection in mice. Clin Exp Immunol 2001; 123: 428–434.
CMI Feng et al. Gender differences in treatment outcomes of TB E337
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E331–E337
